Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Key Documents

View All Documentation

C0691000

Ceftriaxone sodium

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Ceftriaxone disodium salt hemi(heptahydrate)

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C18H16N8Na2O7S3 · 3.5H2O
Numéro CAS:
104376-79-6
Poids moléculaire :
661.60
Numéro CE :
277-930-0
Numéro MDL:
MFCD01750405
Code UNSPSC :
41116107
ID de substance PubChem :
329774815
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

ceftriaxone

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

O.O.O.O.O.O.O.[Na+].[Na+].CO\N=C(/C(=O)N[C@H]1C2SCC(CSC3=NC(=O)C(=O)N([Na])N3C)=C(N2C1=O)C([O-])=O)c4csc(N)n4.CO\N=C(/C(=O)N[C@H]5C6SCC(CSC7=NC(=O)C(=O)N([Na])N7C)=C(N6C5=O)C([O-])=O)c8csc(N)n8

InChI

1S/2C18H18N8O7S3.4Na.7H2O/c2*1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7;;;;;;;;;;;/h2*5,9,15H,3-4H2,1-2H3,(H5,19,20,21,23,27,29,31,32);;;;;7*1H2/q;;4*+1;;;;;;;/p-4/b2*24-8-;;;;;;;;;;;/t2*9-,15-;;;;;;;;;;;/m11.........../s1

Clé InChI

PMRZKYOXTPBIQF-MAODNAKNSA-J

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ceftriaxone sodium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Danger

Mentions de danger

H315,H317,H319,H334,H335

Classification des risques

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 8

1 of 8

USP

USP

1097636

Cefepime hydrochloride

Sulbactam European Pharmacopoeia (EP) Reference Standard

Y0000528

Sulbactam

Cefuroxime VETRANAL®, analytical standard

Supelco

34218

Cefuroxime

vibrant-m

C0682800

Cefazolin

Cefotaxime sodium European Pharmacopoeia (EP) Reference Standard

C0685000

Cefotaxime sodium

Cefotaxime sodium salt potency: 916-964 μg per mg

Sigma-Aldrich

C7912

Cefotaxime sodium salt

Ceftazidime hydrate 90.0-105.0%, contains ~10% sodium carbonate as stabilizer

Sigma-Aldrich

C3809

Ceftazidime hydrate

Méropénème trihydraté Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1772

Méropénème trihydraté

Zhihui Luo et al.
Journal of biomedical nanotechnology, 9(1), 69-76 (2013-05-01)
In this paper, the selectively enhanced antibacterial effects of ZnO nanorods with several kinds of conventional medical antibiotics are investigated. Compares to gentamicin, clarithromycin and ofloxacin, ZnO nanorods could obviously achieve synergistic antibacterial effects with ceftriaxone against Escherichia coli (E.
Filippo Lagi et al.
Journal of travel medicine, 20(2), 128-130 (2013-03-08)
We present the case of two Australian tourists aged 25 and 26  years who, after immersion in a canal in Venice, developed severe leptospirosis. After a 1-week history of fever, headache, myalgia, and vomiting they developed jaundice and renal failure.
Catherine A Ison et al.
The Lancet. Infectious diseases, 13(9), 762-768 (2013-06-15)
Effective treatment of gonorrhoea is fundamental to public health control; however, the ability of Neisseria gonorrhoeae to successively develop resistance to different treatments has hampered control efforts. The extended-spectrum cephalosporins--cefixime and ceftriaxone--have been recommended in the UK for treatment of
Phillip J Read et al.
Sexual health, 10(5), 460-462 (2013-09-14)
Emerging antimicrobial resistance within Neisseria gonorrhoeae (NG) is a significant global public health threat. Detection and investigation of treatment failures is a crucial component of the World Health Organisation's response to this challenge. We report the cases of two homosexual
N Goire et al.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 18(14), 20444-20444 (2013-04-19)
Emergence and spread of Neisseria gonorrhoeae resistant to extended spectrum cephalosporins is a major problem threatening treatment of gonorrhoea and is further highlighted by the recent report of a second ceftriaxone-resistant N. gonorrhoeae strain (F89) in Europe, initially observed in
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique